NZ752214A - Arsenic compositions - Google Patents
Arsenic compositionsInfo
- Publication number
- NZ752214A NZ752214A NZ752214A NZ75221417A NZ752214A NZ 752214 A NZ752214 A NZ 752214A NZ 752214 A NZ752214 A NZ 752214A NZ 75221417 A NZ75221417 A NZ 75221417A NZ 752214 A NZ752214 A NZ 752214A
- Authority
- NZ
- New Zealand
- Prior art keywords
- arsenic trioxide
- arsenic
- compositions
- nahas2o4
- realisation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Abstract
The present invention is predicated on the realisation that problems with the poor water solubility of arsenic trioxide and the extreme difficulty in dissolving arsenic trioxide in anything other than a very basic solution, could be overcome by forming a much more soluble diarsenic tetraoxide, including the compound NaHAs2O4, prior to its delivery to a patient. Pharmaceutical compositions with such compounds and their use in the treatment of cancers is disclosed.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2016904945A AU2016904945A0 (en) | 2016-12-01 | Arsenic compositions | |
PCT/AU2017/050807 WO2018098519A1 (en) | 2016-12-01 | 2017-08-02 | Arsenic compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ752214A true NZ752214A (en) | 2022-11-25 |
Family
ID=62240940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ752214A NZ752214A (en) | 2016-12-01 | 2017-08-02 | Arsenic compositions |
Country Status (20)
Country | Link |
---|---|
US (1) | US11241453B2 (en) |
EP (1) | EP3548044B1 (en) |
JP (2) | JP7080230B2 (en) |
KR (1) | KR102487884B1 (en) |
CN (1) | CN109952105A (en) |
AU (1) | AU2017368444B9 (en) |
BR (1) | BR112019007498A2 (en) |
CA (1) | CA3041357A1 (en) |
CL (1) | CL2019001422A1 (en) |
DK (1) | DK3548044T3 (en) |
ES (1) | ES2964979T3 (en) |
IL (1) | IL265986B (en) |
MX (1) | MX2019006107A (en) |
NZ (1) | NZ752214A (en) |
PE (1) | PE20191544A1 (en) |
PL (1) | PL3548044T3 (en) |
SG (1) | SG11201903064SA (en) |
TW (1) | TWI808060B (en) |
WO (1) | WO2018098519A1 (en) |
ZA (1) | ZA201902156B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20190310A1 (en) | 2016-08-01 | 2019-03-01 | Veolia Water Solutions And Tech Support | PROCESS TO REMOVE SILICA FROM PRODUCED WATER AND OTHER WASTEWATER STREAMS |
IL265986B (en) * | 2016-12-01 | 2022-09-01 | Eupharma Pty Ltd | Pharmaceutical composition comprising an alkali metal and/or an alkaline earth metal diarsenic (iii) tetraoxide and uses thereof |
CA3211092A1 (en) * | 2021-02-26 | 2022-09-01 | Intas Pharmaceuticals Ltd. | Oral pharmaceutical composition of arsenic trioxide |
JP2022151442A (en) * | 2021-03-26 | 2022-10-07 | 均 石井 | Agents for treating leukemia |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2080004A (en) * | 1933-05-17 | 1937-05-11 | Frederick E Dearborn | Double salt of copper arsenite and a copper salt of an unsaturated fatty acid and process of making the same |
US3280046A (en) | 1963-03-27 | 1966-10-18 | Dow Chemical Co | Polyol ether resins and utility |
DE69840057D1 (en) | 1997-10-15 | 2008-11-06 | Polarx Biopharmaceuticals Inc | Pharmaceutical compositions containing arsenic trioxide for the treatment of central nervous system cancer |
ES2395515T3 (en) | 1997-11-10 | 2013-02-13 | Memorial Sloan Kettering Cancer Center | Arsenic trioxide for use in the treatment of leukemia |
CN1471925A (en) * | 2002-08-02 | 2004-02-04 | 丛繁滋 | Arsenic contained composition for directly hard tumour medoicine feed, preparation, preparing method thereof |
US7521071B2 (en) | 2002-10-09 | 2009-04-21 | Versitech Limited | Formulation of oral compositions comprising arsenic trioxide and methods of use thereof |
EP1721615A1 (en) | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
US20090246291A1 (en) | 2008-03-27 | 2009-10-01 | Angelika Burger | Method and compositions for treatment of cancer |
CN102060722B (en) * | 2009-05-01 | 2014-06-11 | 常州高新技术产业开发区三维工业技术研究所有限公司 | Arsenic compound and preparation method and use thereof |
EP2359812A1 (en) | 2010-01-18 | 2011-08-24 | Cephalon France | Oral lyophilised compositions |
CN105435228B (en) * | 2014-08-14 | 2020-08-07 | 中国科学院上海营养与健康研究所 | New anti-tumor application of arsenic trioxide and anti-tumor preparation |
ES2954081T3 (en) * | 2015-01-29 | 2023-11-20 | Eupharma Pty Ltd | Compositions containing arsenic for use in treatment methods |
ES2899226T3 (en) * | 2015-02-01 | 2022-03-10 | Syros Pharmaceuticals Inc | Lyophilized compositions with a high specific surface area containing arsenic intended for oral administration in patients |
IL265986B (en) | 2016-12-01 | 2022-09-01 | Eupharma Pty Ltd | Pharmaceutical composition comprising an alkali metal and/or an alkaline earth metal diarsenic (iii) tetraoxide and uses thereof |
-
2017
- 2017-08-02 IL IL265986A patent/IL265986B/en unknown
- 2017-08-02 PE PE2019000939A patent/PE20191544A1/en unknown
- 2017-08-02 KR KR1020197013881A patent/KR102487884B1/en active IP Right Grant
- 2017-08-02 JP JP2019524985A patent/JP7080230B2/en active Active
- 2017-08-02 TW TW106126050A patent/TWI808060B/en active
- 2017-08-02 DK DK17876251.4T patent/DK3548044T3/en active
- 2017-08-02 NZ NZ752214A patent/NZ752214A/en unknown
- 2017-08-02 PL PL17876251.4T patent/PL3548044T3/en unknown
- 2017-08-02 EP EP17876251.4A patent/EP3548044B1/en active Active
- 2017-08-02 US US16/465,693 patent/US11241453B2/en active Active
- 2017-08-02 WO PCT/AU2017/050807 patent/WO2018098519A1/en unknown
- 2017-08-02 SG SG11201903064SA patent/SG11201903064SA/en unknown
- 2017-08-02 CA CA3041357A patent/CA3041357A1/en active Pending
- 2017-08-02 ES ES17876251T patent/ES2964979T3/en active Active
- 2017-08-02 CN CN201780069613.2A patent/CN109952105A/en active Pending
- 2017-08-02 MX MX2019006107A patent/MX2019006107A/en unknown
- 2017-08-02 AU AU2017368444A patent/AU2017368444B9/en active Active
- 2017-08-02 BR BR112019007498A patent/BR112019007498A2/en active Search and Examination
-
2019
- 2019-04-05 ZA ZA2019/02156A patent/ZA201902156B/en unknown
- 2019-05-27 CL CL2019001422A patent/CL2019001422A1/en unknown
-
2022
- 2022-02-25 JP JP2022028046A patent/JP7419415B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
DK3548044T3 (en) | 2023-12-11 |
IL265986B (en) | 2022-09-01 |
CL2019001422A1 (en) | 2019-08-02 |
WO2018098519A1 (en) | 2018-06-07 |
ZA201902156B (en) | 2021-01-27 |
IL265986A (en) | 2019-06-30 |
JP2020500845A (en) | 2020-01-16 |
PE20191544A1 (en) | 2019-10-24 |
ES2964979T3 (en) | 2024-04-10 |
BR112019007498A2 (en) | 2019-07-02 |
JP2022069485A (en) | 2022-05-11 |
EP3548044A4 (en) | 2020-07-22 |
TW201821087A (en) | 2018-06-16 |
JP7419415B2 (en) | 2024-01-22 |
SG11201903064SA (en) | 2019-05-30 |
US11241453B2 (en) | 2022-02-08 |
KR20190089865A (en) | 2019-07-31 |
CA3041357A1 (en) | 2018-06-07 |
EP3548044B1 (en) | 2023-09-20 |
EP3548044A1 (en) | 2019-10-09 |
MX2019006107A (en) | 2019-08-21 |
CN109952105A (en) | 2019-06-28 |
JP7080230B2 (en) | 2022-06-03 |
AU2017368444A1 (en) | 2019-04-18 |
AU2017368444B2 (en) | 2020-04-30 |
AU2017368444B9 (en) | 2020-07-02 |
KR102487884B1 (en) | 2023-01-11 |
US20200016196A1 (en) | 2020-01-16 |
PL3548044T3 (en) | 2024-03-04 |
TWI808060B (en) | 2023-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ752214A (en) | Arsenic compositions | |
PH12017501956A1 (en) | Compositions of obeticholic acid and methods of use | |
MX2016016666A (en) | Boronic acid derivatives and therapeutic uses thereof. | |
MX2018001721A (en) | 5-bromo-2,6-di-(lh-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer. | |
NZ733174A (en) | Quinazoline derivatives used to treat hiv | |
PH12018500987A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
MX2015008627A (en) | Boronic acid derivatives and therapeutic uses thereof. | |
PH12018502497A1 (en) | Adenosine derivatives for use in the treatment of cancer | |
MX2016011897A (en) | Compositions of selenoorganic compounds and methods of use thereof. | |
EA201691918A1 (en) | PHARMACEUTICAL COMPOSITIONS OF KINAZ INHIBITOR KINAZ OF THE RAF FAMILY, METHODS OF THEIR PRODUCTION AND METHODS OF THEIR USE | |
EA201790726A1 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ULCERAL COLITIS | |
MX2016003238A (en) | Cationic antiseptic compositions. | |
UY35735A (en) | DISTRICTED TRIFLUOROMETILPIRIMIDINONES AND ITS USE | |
PH12018501709A1 (en) | Naphthridinedione derivatives | |
EA032654B9 (en) | [1,2,4]TRIAZOLO[4,3-b]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | |
MX2018007112A (en) | Fast dissolving peroxymonosulfate composition. | |
MX2016004128A (en) | Process for the preparation of xanthohumol. | |
WO2016040814A3 (en) | Disulfide polymers and methods of use | |
WO2015160470A3 (en) | Nadph production by the 10-formyl-thf pathway, and its use in the diagnosis and treatment of disease | |
MX2015012720A (en) | Base addition salts of nitroxoline and uses thereof. | |
NZ757526A (en) | Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction | |
MX2017009659A (en) | Compositions containing arsenic and their use in methods of treatment. | |
WO2016057660A8 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
CL2017001611A1 (en) | A process for the production of n-acetyl-aspartylated iron (iii) casein complexes and use thereof in pharmaceutical compositions | |
SG10201810093PA (en) | Pharmaceutical composition for external use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 AUG 2024 BY SPRUSON + FERGUSON PTY LTD Effective date: 20230703 |